Fernando José Corrales Izquierdo;Jesús Maria Bañales Asurmendi;María Ujue Latasa Sada;MarÍa del Carmen Gil Puig;Jon Lecanda Cordero;Matías Antonio Avila Zaragoza;Maria Carmen Berasain Lasarte;Jesús Ma
发明人:
Matías Antonio Avila Zaragoza,Jesús Maria Bañales Asurmendi,Maria Carmen Berasain Lasarte,Fernando José Corrales Izquierdo,MarÍa del Carmen Gil Puig,María Ujue Latasa Sada,Jon Lecanda Cordero,Jesús Ma
申请号：
US13462991
公开号：
US20120220546A1
申请日:
2012.05.03
申请国别(地区):
US
年份:
2012
代理人:
摘要：
5′-methylthioadenosine (MTA) is described as a compound that is susceptible to inhibiting and/or blocking the epithelial-mesenchymal transition (EMT), a process whereby epithelial cells become mesenchymal cells.The periodical intake of MTA [every 24 h for 21 days] significantly improves fibrosis and the markers for hepatic cellular damage in KO-Mdr2 mice with MTA (28 mg/kg). Following the daily oral administration of MTA, both the expression of EMT markers in the total liver and appreciable signs of fibrosis are significantly reduced, indicating the beneficial effect of MTA on the liver affected by the lack of Mdr2. MTA is proposed to be a safe drug, suitable for oral formulation and without secondary effects, to be used in the prevention and/or treatment of diseases associated with EMT, including chronic cholestatic diseases, fibrosis and cholangiocarcinoma. On the other hand, MTA is proposed for application in anti-tumor therapies by inhibiting or blocking the EMT properties of CSC cells, in order to improve the prognosis of tumor development and the malignancy thereof.
